Forte Biosciences, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 340.7K | $8.82M | 0.00% | Added+9.6% | 2026-03-31 |
| StateStreet | passive | 54.8K | $1.42M | 0.00% | Added+8.1% | 2026-03-31 |
| Wellington | fundamental | 29.5K | $763.82K | 0.00% | New | 2026-03-31 |
| TwoSigma | quant | 15.5K | $401.68K | 0.00% | Trimmed-51.2% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-11 | -1.16 | -1.24 | -6.90% |
| 2026-03-31 | -1.15 | -1.45 | -26.36% |
| 2025-11-14 | -1.07 | -0.99 | +7.26% |
| 2025-08-14 | -1.11 | -0.96 | +13.32% |
| 2025-05-15 | -0.95 | -1.37 | -44.21% |
| 2024-11-14 | -7.12 | -4.54 | +36.28% |
| 2024-08-14 | -4.12 | -6.75 | -63.64% |
| 2024-05-13 | -4.25 | -4.00 | +5.88% |
| 2024-03-18 | -7.00 | -1.00 | +85.71% |
| 2022-11-14 | -3.75 | -4.50 | -20.00% |
| 2022-08-15 | -4.75 | -5.25 | -10.53% |
| 2021-11-08 | -9.31 | -13.50 | -44.97% |
| 2021-08-16 | -10.92 | -10.75 | +1.53% |
| 2021-05-10 | -12.28 | -9.00 | +26.71% |
| 2021-03-16 | -14.83 | 26.00 | +275.28% |
| 2020-11-09 | -7.62 | -11.25 | -47.54% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| FBRX | -32.35% | -37.31% | -30.07% | +124.35% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -35.32% | -32.67% | -26.63% | +111.66% |